Survey of Ophthalmology
Volume 45 , Pages S353-S360 , May 2001

Efficacy and Safety of Bimatoprost in Patients with Elevated Intraocular Pressure: A 30-Day Comparison with Latanoprost

  • Harvey DuBiner, MD

      Affiliations

    • Clayton Eye Center, Morrow, GA USA
    • ,
  • David Cooke, MD

      Affiliations

    • Great Lakes Eye Care, St. Joseph, MI USA
    • ,
  • Monte Dirks, MD

      Affiliations

    • Ophthalmology Service, Brooke Army Medical Center, San Antonio, TX USA
    • ,
  • William C Stewart, MD

      Affiliations

    • Pharmaceutical Research Corporation, Charleston, SC USA
    • ,
  • Amanda M VanDenburgh, PhD

      Affiliations

    • Allergan, Inc., Clinical Ophthalmology, Irvine, CA, USA
    • Corresponding Author InformationReprint address: Dr. Amanda VanDenburgh, Allergan, Inc., Mail Stop T2-4B, 2525 Dupont Drive, Irvine, CA 92612-1599
    • ,
  • Carlos Felix, MS

      Affiliations

    • Allergan, Inc., Clinical Ophthalmology, Irvine, CA, USA

References 

  1. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:487–497
  2. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995;102:1743–1752
  3. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma (a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group). Ophthalmology. 1996;103:138–147
  4. Conover WJ, Iman RL. Rank transformations as a bridge between parametric and nonparametric studies. Am Stat. 1981;35:124–133
  5. Epstein DL, Krug JH, Hertzmark E, et al.  A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects. Ophthalmology. 1989;96:1460–1467
  6. Fleiss JL. Statistical Methods for Rates and Proportions. New York: John Wiley and Sons; 1981;, 2nd ed
  7. Lehmann EL. Nonparametrics: Statistical Methods Based on Ranks. San Francisco, California, Holden-Day, 1975
  8. Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol. 1991;111:51–55
  9. Ritch R, Shields MB, Krupin T. Preface. In:  Ritch R,  Shields MB,  Krupin T editor. The Glaucomas. St. Louis: Mosby; 1996;
  10. Sacca SC, Rolando M, Marletta A, et al.  Fluctuations of intraocular pressure during the day in open-angle glaucoma, normal-tension glaucoma and normal subjects. Ophthalmologica. 1998;212:115–119
  11. Shirakashi M, Iwata K, Sawaguchi S, et al.  Intraocular pressure-dependent progression (a 15-year follow-up). Ophthalmologica. 1993;207:1–5
  12. Singh K, Spaeth G, Zimmerman T, Minckler D. Target pressure—glaucomatologists holey grail. Ophthalmology. 2000;107:629–630
  13. The AGIS Investigators. The advanced glaucoma intervention study (AGIS) . 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429–440
  14. VanDenburgh AM, Laibovitz RA, Felix C. A one-month dose-response study of AGN 192024, a novel antiglaucoma agent, in patients with elevated intraocular pressure. Invest Ophthalmol Vis Sci. 1999;40:S830;[abstract]
  15. VanDenburgh AM, Laibovitz RA, Felix C. A novel ocular hypotensive lipid (initial safety and efficacy of AGN 192024). Invest Ophthalmol Vis Sci. 1998;39(Suppl):S258;[abstract]
  16. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology. 1996;103:126–137
  17. Woodward DF, Andrews SW, Burk RM, Garst ME: Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents. U.S. Patent 5352708, 1994
  18. Woodward DF, Krauss AH-P, Chen J. Replacement of the carboxylic acid group of prostaglandin F2α with a hydroxyl or methoxy substituent provides biologically unique compounds. Br J Pharmacol. 2000;130:1933–1943
  19. Yu M, Ives D, Ramesha CS. Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem. 1997;272:21181–21186
  20. Zeyen T. Target pressures in glaucoma. Bull Soc Belge Ophtalmol. 1999;274:61–65

PII: S0039-6257(01)00212-0

Survey of Ophthalmology
Volume 45 , Pages S353-S360 , May 2001

Article Tools

* Image Usage & Resolution